We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




New Method Designed to Screen Cancer Cells

By LabMedica International staff writers
Posted on 15 Dec 2015
A screening method has been developed that utilizes viscoelastic characteristics to classify many more different types of cancer cells and that could ultimately lead to better treatments for a variety of other diseases.

The method called parallel microfiltration may also have broader applications, including the ability to screen molecules that can alter particular genes and protein levels inside a cell, which could be useful in treating cancer, diabetes, malaria and other diseases.

Scientists at the University of California – Los Angeles (UCLA; CA, USA) placed a mixture of cells and liquid on a porous membrane, and applied air pressure to force the mixture down through tiny pores that have a smaller circumference than the cells. More...
Stiffer cells block the pores so that not much liquid can filter through; for squishier cells, more of the cell-and-liquid mixture passes through. The scientists can use parallel microfiltration to test many different small molecules at once by measuring the filtration of fluid into individual compartments.

The team found that drug-resistant human ovarian cancer cells are softer than their drug-sensitive counterparts, and that more-invasive cancer cells are softer than less-invasive ones. In future studies, the investigators hope to establish whether squishier cancer cells are in fact more harmful than stiffer cancer cells, and whether their softness can be reversed.

Amy C. Rowat, PhD, the lead author of the study, said, “We want to screen cells based on their squishiness or stiffness. We created a technology to probe the deformability of hundreds of cell samples at the same time, so we can identify compounds that make the cells stiffer. Our hope is that we can identify new compounds that can help to prevent the spread of cancer.” The study was published on December 2, 2015, in the journal Scientific Reports.

Related Links:

University of California – Los Angeles 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Drug Testing Assays
Atellica DT 250 Analyzer
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.